Tesofensine: Monoamine Reuptake Inhibitor Research Overview

Tesofensine (research code NS2330) was developed in the early 2000s by NeuroSearch as a research compound for Alzheimer's and Parkinson's disease investigations, based on its monoamine reuptake inhibition profile. The compound was characterized in preclinical models of cognitive function and motor coordination before its research focus expanded to metabolic effects.^[1]

The unexpected metabolic signaling effects observed in Tesofensine preclinical studies, particularly on body weight and food intake in animal models, drew significant subsequent research interest. The proposed mechanism involves enhanced central catecholamine signaling rather than peripheral metabolic pathway effects.^[2]

Tesofensine is studied as a research reference compound. It has not been approved by the FDA for any human therapeutic or medical purpose.

Tesofensine is a small organic molecule, not a peptide:

• Chemical name: (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane

• Molecular formula: C₁₇H₂₃Cl₂NO

• Molecular weight: approximately 328.28 g/mol

• Structural class: tropane derivative

Tesofensine's tropane scaffold is shared with cocaine and several other monoamine transporter inhibitors. The structural class is well-characterized in CNS pharmacology research, with the dichlorophenyl substituent and ethoxymethyl group providing the specific transporter selectivity profile that distinguishes Tesofensine.^[3]

Tesofensine acts as an inhibitor at three monoamine transporters.

Tesofensine inhibits reuptake of three neurotransmitters via inhibition of their respective transporters:

• NET (norepinephrine transporter), most potent inhibition

• DAT (dopamine transporter), intermediate potency

• SERT (serotonin transporter), least potent of the three

This 'triple reuptake inhibitor' profile distinguishes Tesofensine from selective inhibitors that target only one transporter (e.g., SSRIs, SNRIs).^[3]

Inhibition of monoamine transporters increases synaptic concentrations of NE, DA, and 5-HT in brain regions where each is released. This elevated synaptic signaling produces downstream effects on receptor binding, autoreceptor feedback, and gene expression in CNS preclinical models.^[4]

Tesofensine research has spanned several preclinical domains.

The original research context for Tesofensine was Alzheimer's-related preclinical models, with endpoints including memory task performance in rodent models and cholinergic system markers.^[1]

Parkinson's-related preclinical research using MPTP-induced or 6-OHDA-induced dopaminergic loss models has included Tesofensine in experimental arms, examining motor performance endpoints.^[2]

Rodent models of obesity have examined Tesofensine effects on food intake, body weight, and metabolic markers. The observed effects in animal models drew research attention to the compound's metabolic signaling pathway.^[5]

As a small organic molecule, Tesofensine has different stability characteristics than the peptides elsewhere in this catalog.

Tesofensine is supplied in capsule form (60-count, 500mcg per capsule). Storage at room temperature in a cool, dry place is sufficient for the encapsulated material. The compound itself is stable to standard organic storage conditions.

Quality verification for small molecule research compounds includes HPLC for purity, NMR or mass spectrometry for identity confirmation, and trace impurity profiling. Each batch of Instant Peptides Tesofensine ships with a full Certificate of Analysis.

Instant Peptides supplies Tesofensine in 500mcg capsules (60-count bottle) as a research reference compound. Material is supplied to qualified research professionals. Not for human or animal consumption.

View the product page for current pricing and the Certificate of Analysis for the active batch.